Developing a new treatment for cryptosporidiosis caused by a waterborne parasite.
Development of a new marine natural product for the treatment of cryptosporidiosis, an AIDS-defining disease
This study is testing a new treatment called tartrolon E, made from marine bacteria, to help fight cryptosporidiosis, a tough infection that mainly affects people with AIDS, and it looks promising in stopping the parasite from growing.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10846570 on NIH RePORTER |
What this research studies
This research focuses on developing a new therapeutic compound, tartrolon E (trtE), derived from marine symbiotic bacteria, to treat cryptosporidiosis, a serious infection particularly affecting individuals with AIDS. The researchers have found that trtE effectively inhibits the growth of the Cryptosporidium parasite in laboratory settings and shows promise in animal models. The study aims to further evaluate the effectiveness of trtE against different life stages of the parasite and its potential as a broad-spectrum anti-parasitic treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cryptosporidiosis, particularly those who are immunocompromised, such as patients with AIDS.
Not a fit: Patients who do not have cryptosporidiosis or are not immunocompromised may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, effective treatment for cryptosporidiosis, significantly improving health outcomes for patients with compromised immune systems.
How similar studies have performed: Previous research has shown promise in developing anti-parasitic treatments from marine compounds, but this specific approach with trtE is novel.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: O'connor, Roberta M — University of Minnesota
- Study coordinator: O'connor, Roberta M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.